MindBio Therapeutics Corp News

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

AccesswireAug 1 05:20 ET

MindBio Is Exploring Dual Listing on A Senior Exchange With Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3

AccesswireMay 1 05:20 ET

Lender Requests to Convert Loan to MindBio Shares

AccesswireApr 16 06:40 ET

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients With Major Depressive Disorder

AccesswireMar 20 04:50 ET

MindBio Therapeutics Team Members Honoured With Industry Leading Awards

AccesswireNov 21, 2023 08:42 ET

Mindbio Therapeutics Nominated for Company of the Year in Industry Awards

AccesswireOct 26, 2023 08:50 ET

Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research

AccesswireSep 14, 2023 09:45 ET

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder

AccesswireMay 23, 2023 02:35 ET